Anabolic Steroids for On Sale
PT-141 - Dragon Pharma
Bremelanotide 10 mg/vial | Dragon Pharma | Injectable | Libido
Class
Melanocortin agonist
not a PDE5 inhibitor
Half-Life
Not established here
single dose use
Primary Use
Desire
central pathway
Form
10 mg vial
lyophilised powder
Dose
1.75 mg
0.35 ml after recon
Frequency
Max 1 per 24 h
occasional use
Timing
45 minutes before
subcutaneous
Nitrates
Avoid
blood pressure risk
Boldaxyl 300 - Kalpa Pharmaceuticals
Boldenone Undecylenate 300 mg/ml | Kalpa | Injectable
Class
Undecylenate Ester
long acting
Half-Life
~14 days
weekly pin
Primary Use
Lean Mass
appetite, vascularity
Form
10 ml
300 mg/ml
Dose
450-600mg
per week
Frequency
1-2x wks
every 5-7 days
Cycle
12-14 wks
needs time
PCT Start
3 wks
after last pin
Deca 200 / Test E 200 Dragon Pharma
Nandrolone Decanoate 200 mg + Testosterone Enanthate 200 mg · 400 mg/ml
Class
Anabolic Steroid
classic test + deca blend
Half-Life
Test E ~8d · Deca ~15d
long-acting, weekly dosing
Primary Use
Bulking · Joints
mass, strength, recovery
Form
IM injection
weekly or E5D
Dose
400-800 mg/wk
of the blend (200-400 mg each)
Frequency
Weekly / E5D
both esters covered
Cycle Length
12-16 weeks
PCT 3 weeks after last pin
PCT Start
2-3 wks
after last pin
IGF-1 LR3 - Dragon Pharma
Long R3 IGF-1 1 mg/vial | Dragon Pharma | Subcutaneous | Direct IGF-1R agonist
Class
IGF-1R agonist
Long R3 analog
Half-Life
20-30 h
no IGFBP binding
Main Risk
Hypoglycemia
never dose fasted
Form
1 mg
12-25 doses
Dose
40-80 mcg
daily
Timing
Post-workout
with carbs
Cycle
4-8 weeks
then 4+ off
PCT
Not needed
no HPG effect
YK 11 - Dragon Pharma
YK-11 10 mg/tab | Dragon Pharma | Oral | Lean recomp and mass
Class
Steroidal SARM
DHT-derived, partial AR agonist
Half-Life
Not established
single daily dose convention
Primary Use
Lean mass
AR plus myostatin inhibition
Form
10 mg tablet
100 tablets per box
Dose
10 mg
per day
Frequency
Once daily
same time each day
Cycle
6-8 weeks
not longer
PCT Start
Day after last tablet
SERM for four weeks
Toremfine - Dragon Pharma
Toremifene Citrate 20 mg/tab | Dragon Pharma | Oral | PCT and gyno control
Class
Third-gen SERM
triphenylethylene family
Half-Life
5-7 days
steady after two weeks
Primary Use
LH and FSH restart
also blocks breast ER
Form
20 mg tablets
100 tabs per box
Dose
60 mg
three tablets daily
Frequency
Once daily
same hour each day
Cycle
4-6 weeks
starting at peak ester clearance
PCT Start
14 days after
long esters only
Mazdutide - Dragon Pharma
Mazdutide 10 mg/vial | Dragon Pharma | Injectable | Weight loss
Class
Peptide
GLP-1 and glucagon dual agonist
Half-Life
About 7 days
reported 7-45 days in phase 1
Primary Use
Weight loss
appetite and fat oxidation
Form
10 mg vial
lyophilized powder
Dose
1-6 mg
per week, titrated
Frequency
Once weekly
same day each week
Cycle
12 weeks
then review
PCT Start
Not applicable
no HPG suppression
Primobolan 100 - Zyvex Pharmaceuticals
Methenolone Enanthate 100 mg/ml | Zyvex Pharmaceuticals | Injectable | Cutting
Class
Methenolone ester
enanthate, non-aromatizing
Half-Life
~10-14 days
twice weekly pins
Primary Use
Lean mass
slow, clean gains
Form
10 ml vial
100 mg per ml
Dose
300-400 mg
per week, men
Frequency
2x weekly
3.5 days apart
Cycle
10-12 wk
long, gentle block
PCT Start
10-14 days
after last pin
Clomid - Dragon Pharma
Clomiphene Citrate 50 mg/tab | Dragon Pharma | SERM
Class
SERM
selective estrogen receptor modulator
Half-Life
~5-7 days
daily dosing
Primary Use
PCT
restart the axis
Form
30 tabs
50 mg each
Dose
50 mg
per day
Frequency
daily
same time
Cycle
4 weeks
standard PCT
When
Day 1 PCT
after esters clear
Customer Experiences
By Elias K
On August 19, 2025
By Randy M
On July 18, 2025
By Andre C
On August 9, 2025
By Chris J
On June 25, 2025
By Jason M
On June 1, 2025
By Ramon D
On June 30, 2025
By R***T.
On June 1, 2025
By C***H.
On August 1, 2025
By Wick W
On April 20, 2025
By Tyler G
On June 19, 2025
By Martin B
On July 1, 2025
By Bryan N
On June 30, 2025
By W***W.
On July 12, 2025
By MIke S
On April 9, 2026
By Mike R
On August 27, 2025
Better Results. Lower Risk. Fully Informed Choices.
By Marcus J. Reid
On May 11, 2026
By Marcus J. Reid
On April 8, 2026

